ワシントンにおける多発性骨髄腫の臨床試験
ワシントン内の拠点で、多発性骨髄腫に関する30件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07582432A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Puyallup
- Research Site, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Washington, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University of Washington, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06500884A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- NorthWest Medical Specialties, PLLC, Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Northwest Medical Specialties, PLLC, Tacoma
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07609940A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Optum Care Washington, Everett
- American Oncology Network Vista Oncology Division / Physician partner associate, Olympia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Northwest Medical Specialties, Bonney Lake
- Northwest Medical Specialties, Federal Way
- Northwest Medical Specialties, Gig Harbor
- 他4件
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07181941Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
被験者募集中観察研究
2 Months · 全性別 · 2026/09/16更新 · NCT00900198A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Northwest Medical Specialties Tacoma /ID# 272506, Tacoma
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06953960Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Northwest Medical Specialties, Tacoma
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Edmonds
- Research Site, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Puyallup
- Research Site, Seattle
- Research Site, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Fred Hutch Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT02343042A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
- Northwest Medical Specialties Tacoma /ID# 267117, Tacoma
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- VA Puget Sound Health Care System, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/08更新 · NCT05137054Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Harrison Medical Center, Bremerton
- 他15件
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06433947Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Swedish Medical Center - Seattle /ID# 268052, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/12更新 · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Puyallup
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Swedish Cancer Institute, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/20更新 · NCT03761108A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Swedish Medical Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06153251PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
- University of Washington, Seattle
被験者募集中
18歳以上 · 全性別 · 2025/04/20更新 · NCT05956457Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
- University of Washington, Seattle
被験者募集中
18歳以上 · 全性別 · 2024/12/11更新 · NCT05053607Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
- All4Cure, Seattle
被験者募集中観察研究
18歳以上 · 全性別 · 2024/05/03更新 · NCT06149910ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。